Medical device maker Beyond Air's Q2 net loss narrows slightly
Overview
US medical device maker's Q2 revenue rose 28% yr/yr to record level
Company posted Q2 net loss of $7.8 mln, slightly lower than last year
Company reaffirmed 2026 and 2027 revenue guidance; FDA review of new LungFit PH ongoing
Outlook
Company reaffirms revenue guidance of $8 mln for calendar year 2026, excluding second-gen LungFit PH
Beyond Air maintains revenue forecast of $16–$18 mln for calendar year 2027, pending FDA approval
Company expects FDA review of second-gen LungFit PH to conclude after audit readiness in mid-December
Result Drivers
LUNGFIT PH ADOPTION - Co said record revenue growth reflected continued adoption of first-generation LungFit PH system
COMMERCIAL STRATEGY - Enhanced commercial strategy for first-generation LungFit PH supported increased adoption
CUSTOMER SATISFACTION - Co cited pace of new account wins and renewals as evidence of high customer satisfaction with LungFit PH technology
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | $2.32 mln | ||
Q2 Loss Per Share | $3.76 | ||
Q2 Net Loss | $7.82 mln | ||
Q2 Gross Profit | $197,000 | ||
Q2 Operating Expenses | $6.17 mln | ||
Q2 Operating Income | -$5.98 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Beyond Air Inc is $20.00, about 693.7% above its November 10 closing price of $2.52
Reuters Recommended Reads
Nov 10 - Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth
Nov 10 - Surgical robotics firm Stereotaxis' Q3 revenue rises, but misses estimates
Nov 10 - KORU Medical Q3 revenue rises 11% year-over-year
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)